NSE: DRREDDY· HealthCareNot in Aug top-30Large cap

Dr Reddy's Laboratories

Cyclical: bought at the gRevlimid cliff

Last close
₹1,251.90
29 Sept 2026 · reference
1D · 1M
+2.5% · +6.3%
price-only
Weight
0.7%
31 Jul 2026 · Aug rank —
Thesis review
8 Sep 2026
Why We Own, p45
Coverage owner: Research (per book); latest results Q Jun-26Screener ↗Tijori ↗NSE ↗
Map

What must happen → what could break it → what we watch

Catalysts · 3
  • Semaglutide API re-test in Sep-2026 and commercial supply resumption targeted Nov-2026 (6-7 mn pens by Mar-2027).
    C1
  • Abatacept biosimilar US approval decision expected by Dec-2026 (Q4FY27).
    C2
  • Q2FY27 results (late Oct/Nov-2026): evidence of EBITDA margin recovering toward 20%.
    C3
Material risks · 3
  • Semaglutide API quality failure: Rs 240 cr provision already; a second failure or slower re-test (Sep-2026) would push the Nov-2026 relaunch and FY27 EPS cuts already flagged by Emkay (-5%).
    R1
  • USFDA: 7-observation Form 483 at the Bachupally biologics plant (Jun-2026) could delay abatacept approval (Dec-2026 target).
    R2
  • Consensus still expects downgrades: Axis SELL (TP 1,070), Goldman SELL (1,050); US base ex-Revlimid has settled near bear-case levels per Emkay.
    R3
Live monitors
  • Valuation vs approved target
    No target stated
  • Latest reported quarter
    Q Jun-26
  • Results-driven thresholds
    Awaiting approved numbers

Catalysts and risks are the approved one-pager text in full; the register below adds owners and review dates. Monitors read from the price and fundamentals feeds.

Risks as a decision framework

Material risks

Risk register
#Risk (approved text)Owner · next review
01Semaglutide API quality failure: Rs 240 cr provision already; a second failure or slower re-test (Sep-2026) would push the Nov-2026 relaunch and FY27 EPS cuts already flagged by Emkay (-5%).Research · post 2QFY27
02USFDA: 7-observation Form 483 at the Bachupally biologics plant (Jun-2026) could delay abatacept approval (Dec-2026 target).Research · post 2QFY27
03Consensus still expects downgrades: Axis SELL (TP 1,070), Goldman SELL (1,050); US base ex-Revlimid has settled near bear-case levels per Emkay.Research · post 2QFY27

Exposure mechanism, impact and mitigants are as written in the book. Leading indicators and numeric triggers not stated in the approved text remain research tasks rather than being invented.

Catalysts

Observable events

  • 01Semaglutide API re-test in Sep-2026 and commercial supply resumption targeted Nov-2026 (6-7 mn pens by Mar-2027).
  • 02Abatacept biosimilar US approval decision expected by Dec-2026 (Q4FY27).
  • 03Q2FY27 results (late Oct/Nov-2026): evidence of EBITDA margin recovering toward 20%.
Monitors

Live monitors from available data

  • ClearValuation exceeding the approved range: reference close 1,252 vs base target not stated.
  • DataLatest reported quarter in fundamentals: Q Jun-26. Results-driven monitors (growth below thesis threshold, margin, credit cost) need approved numeric thresholds; none in the book.
  • DataInput-cost and capital-allocation monitors require licensed commodity/filings feeds — not configured.